Skip to Content
Merck
All Photos(1)

Key Documents

SML2919

Sigma-Aldrich

Abarelix acetate

Synonym(s):

N-Ac-D-Nal-4-Cl-D-Phe-D-Pal-Ser-N-Me-Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH2, acetate salt, N-Ac-DNal-DCpa-DPal-Ser-Nα-Me-Tyr-DAsn-Leu-ILys-Pro-DAla-NH2, acetate salt, N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, acetate salt, PPI 149 acetate, PPI-149 acetate, PPI149 acetate, R 3827 acetate, R-3827 acetate, R3827 acetate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C72H95ClN14O14 · xC2H4O2
CAS Number:
Molecular Weight:
1416.06 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥97% (HPLC)

Quality Level

form

film or powder

color

white to beige

storage temp.

−20°C

Biochem/physiol Actions

Abarelix (PPI-149) is a gonadotropin releasing hormone (GnRH)/luteinizing hormone releasing hormone (LHRH) receptor (GnRHR, LHRHR) antagonist with low histamine release induction propensity (EC50 = 100 μg/mL; rat mast cells). Abarelix exhibits good in vivo efficacy via iv. or sc. in suppressing LH levels in castrated male rats (plasma LH = 12/1.2/0.9/1.2 ng/mL 6 hrs post 0/12.5/50/200 μg/kg in 5% mannitol sc.) and in lowering testosterone among intact male rats (plasma testosterone = 1.64/0.29 ng/mL 6 hrs post 0/3 μg/kg sc.).

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G Jiang et al.
Journal of medicinal chemistry, 44(3), 453-467 (2001-07-21)
A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P)-D4Aph/D4Amf(Q)-Leu-ILys-Pro-DAla-NH2 was synthesized, characterized, and screened for duration of inhibition of luteinizing hormone release in a castrated male rat assay. Selected analogues were tested in a reporter gene
Pierre Broqua et al.
The Journal of pharmacology and experimental therapeutics, 301(1), 95-102 (2002-03-22)
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists. At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression
Wolfgang Koechling et al.
British journal of clinical pharmacology, 70(4), 580-587 (2010-09-16)
Early studies on gonadotrophin-releasing hormone (GnRH) antagonists pointed out histamine-mediated anaphylactic reactions as a potential adverse effect of these drug candidates. In this study we have compared the histamine-releasing potential of four approved and marketed antagonists, degarelix, cetrorelix, abarelix and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service